医学
心力衰竭
狼牙棒
射血分数
内科学
安慰剂
人口
不利影响
心脏病学
荟萃分析
糖尿病
内分泌学
心肌梗塞
经皮冠状动脉介入治疗
替代医学
环境卫生
病理
作者
Nooraldin Merza,Moeez Akram,Aqsa Mengal,Ahmed Mustafa Rashid,Anber Mahboob,Mawwra Faryad,Zairah Fatima,Muhammad Ahmed,Saad Ali Ansari
标识
DOI:10.1016/j.cpcardiol.2023.101602
摘要
Evaluation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) usage in heart failure (HF) patients with or without type 2 diabetes mellitus (T2DM) could be proven to be a critical breakthrough in treatment options available for these patients. Our study focuses on understanding the safety and efficacy of GLP-1 RAs in this patient population by pooling the data from 9 randomized controlled trials (RCTs) comprising 871 subjects. As compared with the placebo, GLP-1 RAs did not improve major adverse cardiovascular events (MACE) which include cardiovascular (CV) mortality and heart failure (HF) hospitalizations, our primary outcome. CV mortality (RR = 1.03, 95% CI = 0.56-1.88, P = 0.92) and HF hospitalizations (RR = 1.18, 95%CI = 0.93-1.51, P = 0.18). Similarly, GLP-1 RAs did not improve our secondary findings of left ventricular ejection fraction (LVEF) and 6-minute walk test (6MWT). LVEF (RR = 1.96, 95%CI = -0.16-4.07, P = 0.07) or 6 MWT (RR = 8.43, 95% CI = -2.69-19.56, P = 0.14). This meta-analysis shows that GLP-1 RAs do not improve cardiovascular outcomes in HF patients with or without T2DM.
科研通智能强力驱动
Strongly Powered by AbleSci AI